Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib for cognitive and behavioral outcomes in pediatric NF1 with PN and UBOs
ChiCTR2600126875Phase 4Not yet recruiting
- Sponsor
- Jinan Children's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of selumetinib in neurofibromatosis type 1 (NF1), plexiform neurofibroma (PN) and Unidentified bright objects (UBOs) (2 cohorts), sponsored by Jinan Children's Hospital. Primary endpoint: DQ (2–6 years) / IQ (6–16 years). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)plexiform neurofibroma (PN)Unidentified bright objects (UBOs)
Beyond the preview
Go deeper on ChiCTR2600126875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126875.